Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) EBITDA Margin (2016 - 2025)

Veracyte (VCYT) has disclosed EBITDA Margin for 14 consecutive years, with 26.45% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 2293.0% to 26.45% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11.17% through Dec 2025, up 755.0% year-over-year, with the annual reading at 11.17% for FY2025, 755.0% up from the prior year.
  • EBITDA Margin hit 26.45% in Q4 2025 for Veracyte, up from 17.4% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 26.45% in Q4 2025 to a low of 114.07% in Q1 2021.
  • Historically, EBITDA Margin has averaged 13.54% across 5 years, with a median of 10.83% in 2023.
  • Biggest five-year swings in EBITDA Margin: plummeted -7643bps in 2021 and later surged 9158bps in 2022.
  • Year by year, EBITDA Margin stood at 18.32% in 2021, then skyrocketed by 63bps to 6.75% in 2022, then tumbled by -436bps to 36.16% in 2023, then surged by 110bps to 3.52% in 2024, then soared by 652bps to 26.45% in 2025.
  • Business Quant data shows EBITDA Margin for VCYT at 26.45% in Q4 2025, 17.4% in Q3 2025, and 4.05% in Q2 2025.